Abatacept and Certolizumab Interaction
Drug interaction information between Abatacept and Certolizumab.
Abatacept and Certolizumab have a documented moderate interaction in FDA labeling.
FDA drug labeling documents a moderate-severity interaction between Abatacept and Certolizumab. This page displays the available source-record category and label text. The category is not an individual risk estimate or medication-combination direction.
How They Interact
Both of these medicines weaken the immune system to treat inflammation, so taking them together makes it much harder for your body to fight off serious infections.
FDA Label Information
( 7.3 ) 7.1 Use with Anakinra, Abatacept, Rituximab, and Natalizumab An increased risk of serious infections has been seen in clinical studies of other TNF-blocking agents used in combination with anakinra or abatacept, with no added benefit. Therefore, the use of CIMZIA in combination with anakinra, abatacept, rituximab, or natalizumab is not recommended [see Warnings and Precautions (5.8) ] .
Abatacept Also Interacts With
- Adalimumab moderate
- Etanercept moderate
- Golimumab moderate
- Infliximab moderate
Frequently Asked Questions
What SPL severity band is on file for Abatacept + Certolizumab?
Compiled FDA labeling labels this pair moderate. That is a source-record field, not an individual medication-combination decision.
Which drug in this pair has the larger labeled-interaction portfolio?
Abatacept has 5 labeled pairs on file vs Certolizumab's 1. In the moderate band specifically: Abatacept has 5 (also Adalimumab, Etanercept, Golimumab, Infliximab); Certolizumab has 1.
What mechanism field is on file for Abatacept and Certolizumab?
Both of these medicines weaken the immune system to treat inflammation, so taking them together makes it much harder for your body to fight off serious infections.
Abatacept's labeled portfolio outnumbers Certolizumab
SPL source-record counts only. This page's band is moderate · classes on file: Abatacept (T-Cell Co-Stimulation Modulator); Certolizumab (TNF-Alpha Inhibitor (Biologic)).
0 major · 5 moderate · 0 minor · 5 total
- Other moderate peers for Abatacept
- Adalimumab
- Etanercept
- Golimumab
- Infliximab
0 major · 1 moderate · 0 minor · 1 total
Certolizumab has no other moderate-band peer in this dataset besides Abatacept.
Sources: FDA Drug Labels (SPL) via openFDA (2026). This is for informational purposes only and is not medical advice. This registry does not provide individual medication-combination directions.
Read our methodology - how this data is sourced, computed, and verified.